Background and Aim: When carrying out endoscopic submucosal dissection (ESD), procedural safety increases with greater tissue elevation and efficiency increases with longerlasting submucosal cushion. Fluids specifically developed for ESD in Asia are not commercially available in the West, leaving endoscopists to use a variety of injectable fluids off-label. To determine the optimal fluid available in the West, we compared commonly used fluids for Western ESD.
Methods: All phases were carried out in an ex vivo porcine stomach model. Phase 1 compared tissue elevation and duration of submucosal cushions produced by various standard volumes of various injectable solutions used for ESD. The two best-performing solutions used off-label were tested head-tohead in ESD in Phase 2. Phase 3 compared the best solution from Phase 2 to Eleview â , currently the only submucosal injection fluid approved in the USA. In Phases 2 and 3, five ESD were carried out with each solution. The solutions were randomized and the endoscopist blinded to the solution.
Results: The best-performing solutions in Phase 1 were 0.4% hyaluronic acid, 6% hydroxyethyl starch (HES), and Eleview â .
Phase 2 compared 6% HES and hydroxypropyl methylcellulose (HPMC), showing that ESD with 6% HES was easier (P = 0.007), faster (P = 0.041) and required less injection volume (P = 0.003). In Phase 3, resection speed, ease of ESD and total volume per area resected were comparable between 6% HES and Eleview â .
INTRODUCTION

E NDOSCOPIC SUBMUCOSAL DISSECTION (ESD)
is an advanced endoscopic technique for the resection of early malignant lesions of the gastrointestinal tract. The technique uses the potential space of the submucosal layer of the gastrointestinal tract, which can be expanded with fluid injection, creating a dissection plane beneath the lesion. ESD allows higher en bloc and curative resection rates compared to endoscopic mucosal resection, and is less invasive than traditional surgery. 1 National endoscopic screening programs to detect gastric cancer in Japan have resulted in a large number of patients with early gastric cancers. Disease prevalence, and facility with the endoscopic platform have driven ESD to become the standard of care for curative resection of early gastric and esophageal cancers in Japan. 2 The scientific evaluation of ESD-specific injection solutions occurred in parallel with development of procedural technique. 2, 3 Although no consensus for the ideal solution exists, glycerol and 0.4% sodium hyaluronic acid solutions are the most commonly used. 2, 3 Migration of ESD techniques to the West has been challenged by the lack of ESD-specific injectable fluids developed in Japan. By convention, normal saline is widely used in the West, but this was a solution of convenience and lacks an evidentiary evaluation. Normal saline rapidly diffuses into surrounding tissue, necessitating time-consuming repeat injections throughout ESD procedures. The little data specific to injection solutions in the published literature suggest that increased longevity and degree of submucosal expansion increases both safety and efficiency of ESD procedures. 2 Sustained submucosal expansion is more vital for ESD in the West, given the more common performance in the thinner-walled esophagus and colon.
In addition to providing long-lasting tissue elevation, characteristics of an ideal ESD solution would include broad availability, low cost, non-toxicity, an no interference with tissue architecture or later tissue processing that may compromise histological review. [2] [3] [4] The aim of the present study was to determine the optimal injection fluid for ESD available in the West. Injectable solutions with a literature precedent for off-label use by Western endoscopists and solution with a labelled indication for submucosal injection were compared in an ex vivo porcine stomach ESD model.
METHODS
Selection of injection solutions
A PUBMED LITERATURE search was undertaken to identify prior studies of injectable solutions used to carry out ESD for inclusion in this study (keywords: [ESD AND submucosal injection solution]; [EMR AND submucosal injection solution]; [endoscopic submucosal dissection AND submucosal injection solution AND gastrointestinal tract]). Several commonly available crystalloid solutions were identified for inclusion: 0.9% sodium chloride solution (normal saline), 3% sodium chloride solution (hypertonic saline), 5% dextrose in water (D5W), and 5% dextrose in 0.9% sodium chloride solution (D5NS). 4, 5 Hydroxypropyl methylcellulose (HPMC), widely available as an ophthalmic lubricant (Gonak â 2.5%; Akorn Inc., Somerset, NJ, USA) was included. 4, 6 Per prior reports, 15 mL of the viscous HPMC concentrate was diluted in 85 mL normal saline. 5 A solution of 6% hydroxyethyl starch (HES) is typically used as an i.v. volume expander (Voluven â ; Fresenius Kabi, Bad Homburg vor der H€ ohe, Germany), is commonly used off-label for ESD, and was also included. Other solutions that were considered for this study but were either investigational or commercially unavailable in the USA included: succinylated gelatin, fibrinogen mixture, autologous blood, carboxymethylcellulose, photo cross-linkable chitosan hydrogel, and solutions with auto-dissection properties. In Japan, 0.4% sodium hyaluronic acid is commonly used to carry out ESD. This solution was prepared by the Cleveland Clinic Investigational Pharmacy at our institution as an Eastern control in Phase 1 of the study. 
Study design
This study was divided into three phases to determine the optimal submucosal injection solution.
Phase 1: Durability and tissue elevation of standard volume injections Phase 1 was undertaken to determine the degree and duration of submucosal expansion by the included solutions. A standardized 2-mL volume of each solution was injected into the submucosa from the mucosal surface of an ex vivo porcine stomach using a 1-inch-long 25-gauge needle. To minimize possible effects of variable tissue thickness, all injections were made in the proximal gastric body. The height of mucosal elevation was measured using a ruler at 1, 2, 3, 5, 7, 10, 15, and 20 min after injection, with six trials per solution.
Phase 2: Blinded assessment of off-label injectable solutions
Phase 2 of this study was a blinded, head-to-head comparison of the two best performing off-label solutions using an ex vivo porcine stomach ESD model. The two non-control solutions that maintained the longest-lasting submucosal elevation from Phase 1 were selected. An ESD-qualified advanced endoscopist (A.B.) carried out ESD on a standard 3-cm-diameter lesion in an ex vivo porcine stomach. The fluid used during each procedure was randomized and the endoscopist was blinded to the injectate used, and five ESD procedures were carried out per solution. Primary outcome was ESD efficiency measured in terms of resection speed (minutes to complete procedure/surface area of resected lesion). Secondary outcomes were total ESD procedure time, total number of fluid injections, total fluid volume, and ease of dissection assessed using a 100-mm visual analog scale (VAS), ranging from extremely difficult (lower scores) to relatively easy (higher scores).
Phase 3: Blinded assessment of off-label and on-label injectable solutions
Phase 3 of this study was a blinded, head-to-head comparison of injection solutions. During this phase, the solution from Phase 2 allowing the best resection speed was compared to Eleview â . To highlight the differences in the injection fluids and minimize endoscopic skill affecting resection times, all procedures were carried out by an advanced endoscopist training in ESD procedures (M.F.). The fluid used during each procedure was randomized and the endoscopist was blinded, with five ESD procedures carried out per solution. In contrast to Phase 2, the surface area of the resected specimens was analyzed with ImageJ software. 7 
Ex vivo porcine stomach ESD model
The ex vivo porcine models used for ESD were stomachs with an intact esophagus harvested from 6-to 9-month-old Sus scrofa domestic pigs. The stomachs were frozen for transport and thawed at room temperature 12 h prior to each experimental endoscopy session. Water lavage of the gastric lumen cleared residual food or debris. The stomachs were placed into a 19 9 13 9 4.5-inch plastic tray for stabilization. The esophagus was passed through a hole in the tray and secured around a short Guardus â Overtube (US Endoscopy, Mentor, OH, USA). All procedures were carried out in the dependent portion of the proximal gastric body to minimize variation in tissue thickness and eliminate gravity-assisted retraction. All ESD procedures were carried out with a GIF-H190 upper endoscope (Olympus, Center Valley, PA, USA) fitted with a disposable straight soft distal attachment (D-201-11804; Olympus, Tokyo, Japan). An Erbe VIO â 300D electrosurgical generator (ERBE, T€ ubingen, Germany) with the following electrosurgery settings was used: Endo Cut Effect 3, and Dry Cut Effect 2. A coagulation setting was not needed as there was no bleeding in the ex vivo porcine stomach. Submucosal injections were carried out using a 25 gauge CarrLocke injection needle (US Endoscopy, Mentor, OH, USA). The DualKnife TM (KD-650U; Olympus) was the only knife used. A marked wire (ACRO-25-260; Cook Medical, Bloomington, IN, USA) was used to estimate a 3 9 3 cm lesion for Phase 2. Procedural steps for ESD procedures were standardized: circumferential marking around the target area, submucosal expansion by fluid injection, circumferential mucosal incision beginning at the 6 o'clock position, then submucosal dissection. The endpoint was when the lesion was completely free of all tissue attachments.
Statistics
Data are presented as mean and standard deviation for all repeated trials. In Phase 1, a linear mixed effects regression analysis with random intercept was created with mucosal elevation height modeled as the outcome, and solution, time and an interaction term as the independent variables. All comparisons in Phase 1 were adjusted for multiple comparisons using Tukey's test. Student's t-tests were used for comparisons in Phase 2 and 3. All analyses were done using SAS (version 9.4, The SAS Institute, Cary, NC, USA) and P < 0.05 was considered significant. (Fig. 1) .
RESULTS
As seen in Figure 1 , the greatest mean tissue elevation at 1 min was obtained by 6% HES (9. Phase 2: Blinded assessment of off-label injectable solutions
The control solutions from Phase 1 (0.4% hyaluronic acid and Eleview â ) were not included in Phase 2. Randomized head-to-head comparison was thus made between 6% HES and HPMC in an ex vivo porcine stomach ESD model. As seen in Table 2 , ESD procedures carried out with 6% HES were more efficient than those completed with HPMC in terms of resected area per unit time (2.1 AE 0.3 vs 1.5 AE 0.3 cm 2 /min, P = 0.017). In addition, ESD procedures with 6% HES took less time overall (P = 0.041), required less injected volume (P = 0.036) and were easier to carry out (P = 0.007). No full-thickness injuries were observed with either solution.
Phase 3: Blinded assessment of off-label and on-label injectable solutions
In a head-to-head comparison of the best performing offlabel solution and Eleview â (on-label), there was little difference, as seen in Table 3 . In terms of primary outcome Greater duration of the submucosal cushion reduces re-injections, sparing instrument changes and reducing time. This allows the endoscope to remain within the submucosal plane, preserving tissue retraction and orientation. Several factors contribute to dissipation of submucosal cushion. First, the injectate leaks directly through the needle hole at the mucosal injection site. Injectates also diffuse into the extracellular space, an effect that occurs most rapidly with isotonic or near-isotonic crystalloid solutions such as normal saline. Respiratory movement, peristalsis and blood flow may promote more rapid distribution. Last, as the connective tissue is divided during ESD, additional fluid is lost directly and by evaporation as a result of heat generated by the electrocautery Hyaluronic acid and glycerol solutions are the most widely used solutions to carry out ESD in Japan. Hyaluronic acid is a glycosaminoglycan component of the extracellular matrix and creates a viscoelastic solution when dissolved. Apart from ESD, hyaluronic acid is used for intra-articular injections to treat osteoarthritis pain or eye surgery. 2, 3 Multiple randomized studies have evaluated various concentrations of hyaluronic acid (0.13%, 0.2%, 0.4%), which collectively show higher rates of successful en bloc resection and fewer complications compared to other solutions. 2, 3, 8, 9 In Japan, commercially available hyaluronic solution is under the trade name MucoUp â (Johnson & Johnson, Tokyo, Japan); 2 however this is not commercially available in the USA or in the remainder of the Western hemisphere. Glycerol is a hypertonic solution of 10% glycerin and 5% fructose in normal saline. When compared to normal saline, glycerol is associated with greater likelihood of en bloc resection with similar complication rates. 10 However, heat from electrosurgical devices creates smoke and impairs visualization. 3 Typically used as a colloidal volume expander sold under the trade name Voluven â (Fresenius Kabi Norge AS, Oslo, Norway), the safety of 6% HES has previously been shown in human trials. Compared to normal saline, 6% HES solution produced a more prolonged submucosal cushion and lower total procedure time for endoscopic mucosal resection. 11 Although use of 6% HES for fluid resuscitation in critically ill patients has been linked to increased mortality, acute kidney injury, and need for dialysis, 12, 13 there have been no safety concerns raised for its use as an injectable 14 Concentrated HPMC must be diluted to reach a viscosity suitable for injection through an endoscopic needle, which introduces opportunity for error in clinical use. Reported HPMC-associated antigenic reactions leading to local inflammation and possible tissue damage at injection sites may hamper its use. 2, 3, 15 Although ESD already offers a significant cost advantage compared to surgical intervention, reducing the cost of consumables during ESD offers further economic advantage. Hyaluronic acid is the most expensive solution, ranging from $4950 to $12 800 per 100 ml (Table 4) . 2 However, as hyaluronic acid has been studied in formal clinical trials, it is often the only solution reimbursed by insurance in the West. 8, 9 Eleview â , commercially packaged as 10-mL ampules, costs $405 for 50 mL. Combining the cost of methylene blue with the cost of 100 mL of 6% HES is $235.21. In general, the crystalloid solutions are less expensive, as they are both readily stocked and generically available. Contract pricing at individual hospitals may differ from these reported costs.
Several potential limitations could be considered when interpreting the present study. First, this is not a comprehensive evaluation of all fluids used to carry out ESD, largely driven by limitations in product availability. However, efforts were made to choose solutions with at least some literature precedent and broad availability. This study was done using ex vivo porcine stomachs. In clinical practice, or in a live animal model, blood flow, peristalsis, respirophasic tissue movement or other physiological factors may differentially affect the rate at which fluid diffuses into tissue, and thus the durability of the cushion. Although a more realistic test, live porcine models and human testing carry increased cost and ethical burden. This study was also limited to ESD of the stomach; it is possible that anatomical and tissue level differences throughout the gastrointestinal tract would lead to different performance characteristics. The present study did not include histological evaluation of resection lesions. However, human ESD carried out at our institution with Eleview â and 6% HES have well-preserved histological features on pathological review.
In conclusion, Eleview and 6% HES were the best-performing Western solutions for ESD as tested in a porcine model.
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